Revance and Mylan to Extend Biosimilar to BOTOX Program Decision Beyond April 30, 2020

 Revance and Mylan to Extend Biosimilar to BOTOX Program Decision Beyond April 30, 2020

Revance and Mylan to Extend Biosimilar to BOTOX Program Decision Beyond April 30, 2020

Shots:

  • Revance is in discussion with Mylan regarding whether Mylan plans to move forward or not with the biosimilar to BOTOX program. The expected decision date for Mylan is Apr 30, 2020 or thirty days from the date that Revance provides Mylan with certain deliverables regarding the program
  • In Sept’2019, the companies amended their agreement to include an additional $5M to Revance in exchange for an extended decision period for Mylan to move forward with a development program. Revance has carried out additional characterization work and analysis for the benefit of the program
  • In Feb 2018, the companies collaborated for development and regulatory approval of BOTOX’s biosimilar. Revance received $25M as upfront and granted commercialization rights to Mylan in the US, EU and ROW

Click here ­to­ read full press release/ article | Ref: Revance | Image: Revance

Related News: Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post